YWHAQ and pulmonary embolism: The demonstration that 14-3-3ζ deficiency protects from fatal pulmonary embolism in mice raises the interesting possibility that 14-3-3 inhibitors may have the added benefit of reducing thrombotic complications during cancer therapy.